Dyslipidemia in liver cirrhosis: Pathophysiology and emerging therapeutic approaches

doi:10.4254/wjh.v18.i3.115539

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 3

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (13)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-2)

Sum=44

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=13

Mar 27, 2026 (publication date) through Mar 26, 2026

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Hepatol. Mar 27, 2026; 18(3): 115539
Published online Mar 27, 2026. doi: 10.4254/wjh.v18.i3.115539

Open in New Tab Full Size Figure Download Figure

Figure 1 Molecular mechanisms of dyslipidemia in liver cirrhosis. Progressive hepatocellular dysfunction, cholestasis, and inflammation alter apolipoprotein synthesis, lipoprotein remodeling, and receptor-mediated clearance, promoting lipid imbalance and oxidative injury. ApoA1: Apolipoprotein A1; ApoB₁₀₀: Apolipoprotein B100; VLDL: Very low-density lipoprotein; HDL: High-density lipoprotein; HMG-CoA: 3-hydroxy-3-methylglutaryl coenzyme A; ACAT: Acyl-coenzyme A cholesterol acyltransferase; LDL-C: Low-density lipoprotein cholesterol; HDL-C: High-density lipoprotein cholesterol; IL: Interleukin; TNF: Tumor necrosis factor; SREBP-2: Sterol regulatory element-binding protein 2; PPAR: Peroxisome proliferator-activated receptor.

Citation: Fuentes-Mendoza JM, Concepción-Zavaleta MJ, Mendoza-Godoy JJ, Concepción-Urteaga LA, Martínez-Gutiérrez CO, Paz-Ibarra J. Dyslipidemia in liver cirrhosis: Pathophysiology and emerging therapeutic approaches. World J Hepatol 2026; 18(3): 115539
URL: https://www.wjgnet.com/1948-5182/full/v18/i3/115539.htm
DOI: https://dx.doi.org/10.4254/wjh.v18.i3.115539